Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Diseases of the Thyroid

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 47 articles:
HTML format

Single Articles

    July 2021
  1. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available

  2. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available

    March 2021
  3. SEIFERT R, Schafers MA, Heitplatz B, Kerschke L, et al
    Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.
    J Nucl Med. 2021 Mar 26. pii: jnumed.121.261898. doi: 10.2967/jnumed.121.261898.
    PubMed     Abstract available

    February 2021
  4. MARIANI G, Tonaccehra M, Grosso M, Fiore E, et al
    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.251504. doi: 10.2967/jnumed.120.251504.
    PubMed     Abstract available

  5. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    PubMed     Abstract available

    October 2020
  6. MARIANI G, Tonacchera M, Grosso M, Orsolini F, et al
    The role of nuclear medicine in the clinical management of benign thyroid disorders. Part 1. Hyperthyroidism.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.243170. doi: 10.2967/jnumed.120.243170.
    PubMed     Abstract available

    July 2020
  7. GRIMALDI S, Lagarde S, Harle JR, Boucraut J, et al
    Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies.
    J Nucl Med. 2020 Jul 24. pii: jnumed.120.249292. doi: 10.2967/jnumed.120.249292.
    PubMed     Abstract available

    May 2020
  8. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available

    April 2020
  9. PICCARDO A, Trimboli P, Bottoni G, Giovanella L, et al
    Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy. A systematic review and meta-analysis.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.244384. doi: 10.2967/jnumed.120.244384.
    PubMed     Abstract available

    March 2020
  10. DONOHOE KJ, Aloff J, Avram AM, Bennet KG, et al
    Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer.
    J Nucl Med. 2020;61:375-396.

  11. WU D, Gomes Lima CJ, Bloom G, Burman KD, et al
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After (131)I Therapy for Thyroid Cancer.
    J Nucl Med. 2020;61:397-404.
    PubMed     Abstract available

    January 2020
  12. VERMANDEL M, Debruyne P, Beron A, Devos L, et al
    Management of patients with renal failure undergoing dialysis during (131)I therapy for thyroid cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.232017. doi: 10.2967/jnumed.119.232017.
    PubMed     Abstract available

    October 2019
  13. GREENSPAN BS, Siegel JA, Hassan A, Silberstein EB, et al
    There is No Association of Radioactive Iodine Treatment with Cancer Mortality in Patients with Hyperthyroidism.
    J Nucl Med. 2019 Oct 4. pii: jnumed.119.235929. doi: 10.2967/jnumed.119.235929.

  14. CHEN W, Dilsizian V
    Radioactive Iodine Treatment and Cancer Mortality in Hyperthyroid Patients: Concerns with Study Design and Bias.
    J Nucl Med. 2019 Oct 4. pii: jnumed.119.234849. doi: 10.2967/jnumed.119.234849.

    September 2019
  15. ROTTENBURGER C, Nicolas GP, McDougall L, Kaul F, et al
    Cholecystokinin-2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.
    J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031.
    PubMed     Abstract available

    August 2019
  16. LIU J, Liu R, Shen X, Zhu G, et al
    The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts the Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer.
    J Nucl Med. 2019 Aug 2. pii: jnumed.119.227652. doi: 10.2967/jnumed.119.227652.
    PubMed     Abstract available

    June 2019
    Sites Performing Dosimetry for Selection of Activity for (131)I Therapy for Differentiated Thyroid Cancer.
    J Nucl Med. 2019;60:20N-22N.

    March 2019
  18. ROLL W, Markwardt NA, Masthoff M, Helfen A, et al
    Multispectral optoacoustic tomography of benign and malignant thyroid disorders - a pilot study.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222174. doi: 10.2967/jnumed.118.222174.
    PubMed     Abstract available

    February 2019
  19. WATABE T, Kaneda-Nakashima K, Liu Y, Shirakami Y, et al
    Enhancement of astatine-211 uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha therapy of thyroid cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.222638. doi: 10.2967/jnumed.118.222638.
    PubMed     Abstract available

    November 2018
  20. SELVAKUMAR T, Nies M, Klein Hesselink MS, Brouwers AH, et al
    Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma.
    J Nucl Med. 2018 Nov 30. pii: jnumed.118.212449. doi: 10.2967/jnumed.118.212449.
    PubMed     Abstract available

  21. ELMOKH O, Taelmann V, Radojewski P, Roelli MA, et al
    MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.216721. doi: 10.2967/jnumed.118.216721.
    PubMed     Abstract available

    October 2018
  22. DE ROSE F, Braeuer M, Braesch-Andersen S, Otto AM, et al
    Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.219105. doi: 10.2967/jnumed.118.219105.
    PubMed     Abstract available

  23. BIKAS A, Wu D, Bethancourt E, Orquiza M, et al
    Detection at public facilities of (131)I in patients treated for differentiated thyroid cancer: the frequency, sites, management by security agents, and recommended physician documentation for patients.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.213256. doi: 10.2967/jnumed.118.213256.
    PubMed     Abstract available

  24. BACHER R, Hohberg M, Dietlein M, Wild M, et al
    Thyroid uptake and effective half-life of radioiodine in thyroid cancer patients at radioiodine therapy and follow-up whole-body scintigraphy either in hypothyroidism or under rhTSH.
    J Nucl Med. 2018 Oct 12. pii: jnumed.118.217638. doi: 10.2967/jnumed.118.217638.
    PubMed     Abstract available

    September 2018
  25. KREISSL M, Janssen M, Nagarajah J
    Current treatment strategies in metastasized differentiated thyroid cancer.
    J Nucl Med. 2018 Sep 6. pii: jnumed.117.190819. doi: 10.2967/jnumed.117.190819.
    PubMed     Abstract available

    August 2018
  26. SCHENKE S, Seifert P, Zimny M, Winkens T, et al
    Risk stratification of thyroid nodules using Thyroid Imaging Reporting And Data System (TIRADS): The omission of thyroid scintigraphy increases the rate of falsely suspected lesions.
    J Nucl Med. 2018 Aug 10. pii: jnumed.118.211912. doi: 10.2967/jnumed.118.211912.
    PubMed     Abstract available

    June 2018
  27. PRYMA DA
    Controversies in the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data.
    J Nucl Med. 2018 Jun 22. pii: jnumed.118.214197. doi: 10.2967/jnumed.118.214197.

    May 2018
  28. SCHMIDT M, Gorges R, Drzezga A, Dietlein M, et al
    Radioiodine therapy in differentiated thyroid cancer - a matter of controversy - PRO Radioiodine.
    J Nucl Med. 2018 May 10. pii: jnumed.117.191338. doi: 10.2967/jnumed.117.191338.
    PubMed     Abstract available

    April 2018
    Controversial Issues in Thyroid Cancer Management.
    J Nucl Med. 2018 Apr 13. pii: jnumed.117.192559. doi: 10.2967/jnumed.117.192559.
    PubMed     Abstract available

  30. TULCHINSKY M, Binse I, Campenni A, Dizdarevic S, et al
    Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.211359. doi: 10.2967/jnumed.118.211359.

    March 2018
  31. SPANU A, Nuvoli S, Gelo I, Mele L, et al
    The role of diagnostic (131)I-SPECT/TC in patients with papillary thyroid microcarcinoma in long-term follow-up.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.204636. doi: 10.2967/jnumed.117.204636.
    PubMed     Abstract available

    December 2017
  32. TESSELAAR MH, Crezee T, Schuurmans I, Gerrits D, et al
    Digitalis-like compounds restore hNIS expression and iodide uptake capacity in anaplastic thyroid cancer.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.200675. doi: 10.2967/jnumed.117.200675.
    PubMed     Abstract available

    October 2017
  33. VASSAUX G, Zwarthoed C, Signetti L, Guglielmi J, et al
    Iodinated contrast agents perturb iodide uptake by the thyroid independently of free iodide.
    J Nucl Med. 2017 Oct 19. pii: jnumed.117.195685. doi: 10.2967/jnumed.117.195685.
    PubMed     Abstract available

  34. PATTISON DA, Bozin M, Gorelik A, Hofman MS, et al
    18F-fluorodeoxyglycose-avid thyroid incidentalomas: the importance of contextual interpretation.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.198085. doi: 10.2967/jnumed.117.198085.
    PubMed     Abstract available

  35. WERNER RA, Schmid JS, Higuchi T, Javadi MS, et al
    Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.199778. doi: 10.2967/jnumed.117.199778.
    PubMed     Abstract available

    April 2017
  36. DEANDREIS D, Schlumberger M, Tuttle RM
    Reply: Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.193185. doi: 10.2967/jnumed.117.193185.

  37. NICHOLS KJ, Robeson W, Yoshida-Hay M, Zanzonico PB, et al
    Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.192278. doi: 10.2967/jnumed.117.192278.
    PubMed     Abstract available

  38. O' DOHERTY J, Jauregui-Osoro M, Brothwood T, Szyszko T, et al
    18F-tetrafluoroborate (18F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252.
    PubMed     Abstract available

  39. JENTZEN W, Nahum AE, Bockisch A, Binse I, et al
    Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192872. doi: 10.2967/jnumed.117.192872.

    March 2017
  40. KIM EE
    Thyroid Cancer: A Comprehensive Guide to Clinical Management; Third Edition.
    J Nucl Med. 2017 Mar 23. pii: jnumed.117.193177. doi: 10.2967/jnumed.117.193177.

    February 2017
    Prescribed activities of I-131 therapies in differentiated thyroid cancer: Invited Commentary.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.188862. doi: 10.2967/jnumed.116.188862.

  42. SOLNES LB, Jones KM, Rowe SP, Pattanayak P, et al
    Diagnostic Value of 18F-FDG PET/CT versus MRI in the Setting of Antibody Specific Autoimmune Encephalitis.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.184333. doi: 10.2967/jnumed.116.184333.
    PubMed     Abstract available

  43. FLUX GD, Verburg FA, Chiesa C, Bardies M, et al
    Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.
    J Nucl Med. 2017 Feb 9. pii: jnumed.116.186643. doi: 10.2967/jnumed.116.186643.

    January 2017
  44. PLYKU D, Hobbs RF, Huang K, Atkins F, et al
    Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.179366. doi: 10.2967/jnumed.116.179366.
    PubMed     Abstract available

    October 2016
  45. LANGEN B, Rudqvist N, Helou K, Forssell-Aronsson EB, et al
    Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Non-Thyroid Tissues.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.176958.
    PubMed     Abstract available

  46. DEANDREIS D, Rubino C, Tala H, Leboulleux S, et al
    Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.179606.
    PubMed     Abstract available

  47. SELIVANOVA S, Lavallee E, Senta H, Caouette L, et al
    Clinical Trial Using Sodium Pertechnetate 99mTc Produced with Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.178509.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.